CDKN2A and cancer: Since ERE73s-ARF (−13) constructs showed lower promoter activity than the E2F1 promoter in all cancer cell lines tested (Figure 1E), we wanted to determine whether activity of ERE73s-ARF (−13) constructs is sufficient to drive HSV-TK gene expression and suppress tumor growth in vivo.